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1. Introduction 
Tuberculosis (TB) is one of the leading infectious disease killers in the world, especially in 
developing countries. The increasing frequency of human-to-human transmission of 
multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium 
tuberculosis poses challenges for effective therapeutic options and infection control. MDR-TB 
is defined as a form of TB that is resistant to at least isoniazid and rifampin, which are used 
to treat all TB patients. XDR-TB is a form of TB that is resistant to at least rifampicin and 
isoniazid in addition to any fluoroquinolone, and at least one of the three injectable second-
line anti-TB drugs (amikacin, capreomycin and kanamycin). Based on the WHO Report 
2010, China was ranked number one among high burden countries in terms of the estimated 
number of MDR-TB cases in 2008, and number two in terms of total numbers of TB cases in 
the world with the incidence rate per capita of 99 per 100,000 populations (WHO, 2011). 
Guizhou province is one of the highest-incidence-rate areas in China, and its prevalence of 
drug-resistant TB is higher than most of other provinces of China (Chen et al., 2011). The 
Affiliated Hospital of Zunyi Medical College is one of the specialized centers in Guizhou 
certified by the provincial government for the treatment of MDR-TB patients.  In 2010, more 
than 15,000 TB patients were treated at the hospital. In order to determine the molecular 
characteristics of drug-resistant TB and assist in making informed TB treatment decisions for 
TB patients in the Zunyi area of Guizhou province, hundreds of M. tuberculosis clinical 
isolates were collected at the Affiliated Hospital of Zunyi Medical College and used for the 
systematic surveillance and other studies. We have made some progresses in the detection 
and molecular characterization of drug-resistant M. tuberculosis clinical isolates using 
different research methods such as M. tuberculosis culture, spoligotyping, gene sequencing, 
proteomics and drug susceptibility testing against first-line and second-line anti-
tuberculosis drugs. 
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In this chapter, we will briefly review the recent advances in the area of MDR-TB research; 
provide detailed descriptions about our research methods and the summary of our current 
research progresses.  This chapter is written for researchers, scientists and physicians in 
academic institutions, clinical laboratories, pharmaceutical companies and research 
hospitals. This chapter will also be suitable for readers such as undergraduate, graduate and 
medical students who wish to learn more about the drug-resistant M. tuberculosis, especially 
MDR/XDR-TB, and some of the current research methods used for the determination of the 
genetic diversity and anti-tuberculosis drug susceptibility profile of M. tuberculosis clinical 
isolates, and the detection of drug-resistant M. tuberculosis. 
2. Survey of drug-resistant M. tuberculosis clinical isolates 
Mycobacteria are aerobes and grow most successfully in tissues with high oxygen content. 
The suitable growth temperature for mycobacteria is 37°C. Mycobacteria are "acid-fast 
bacilli" (AFB) because of their lipid-rich cell walls, which are relatively impermeable to 
various basic dyes unless the dyes are combined with phenol. Once stained, mycobacteria 
are resistant to decolorization with acidified organic solvents. M. tuberculosis is an 
intracellular pathogen usually infecting mononuclear phagocytes, and slow-growing with a 
generation time of 18 to 22 hours. The diagnosis of tuberculosis usually requires the 
detection of acid-fast bacilli in sputum via the acid-fast staining method (Ziehl-Neelsen 
method), which uses carbolfuchsin as the stain, acid-alcohol as the destaining solution and 
methylene blue as the counterstain. The culture confirmation of M. tuberculosis is the gold 
standard for diagnosis of tuberculosis and the drug susceptibility testing (DST) provides the 
basis for surveillance of drug-resistant TB and for physicians to adjust chemotherapy.  
Even though TB laboratory services formed an essential part of the DOTS (Directly 
Observed Treatment Short course) strategy for National Tuberculosis Programs, it was often 
the most neglected component of these programs because of the absence of  standardized 
techniques which complicated the activities of new laboratory services. Based on those 
considerations, WHO prepared guidelines in 1998 for laboratory services for the framework 
of National Tuberculosis Programs (WHO, 1998). The guidelines included three detailed 
manuals, two of which focused on the technical aspects of TB microscopy and culture, and a 
third one dealt with laboratory management including lab safety and proficiency testing. 
These manuals were specifically developed for use in low- and middle-income countries 
with high TB prevalence and incidence rates (WHO, 1998). Most of the methods used in our 
laboratory at the Affiliated Hospital of Zunyi Medical College and described in this chapter 
are based on these three manuals. 
2.1 Collection of sputum specimens from patients 
M. tuberculosis may be isolated from various clinical specimens, including respiratory 
specimens such as sputum, body fluids and body tissues (Goodwin, 2007). TB clinical strains 
from sputum of patients with active pulmonary tuberculosis were collected at the Affiliated 
Hospital of Zunyi Medical College. Sputum specimens were collected into a sterile single-
collection Universal container (28ml) with a tightly fitted lid. A good sputum specimen is 
considered to be recently-discharged materials from the bronchial tree of the patient, with a 
minimum amount of oral or nasal materials (WHO, 1998). In an ideal situation, a sputum 
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specimen produced by a deep cough of the patient should have a volume of 5 to 10 ml, 
although less volumes are acceptable if the quality is good. All sputum specimens should be 
transported to the laboratory and processed as soon as possible after collection. If delay is 
unavoidable, the sputum specimens should be refrigerated to inhibit the growth of 
unwanted microorganisms. 
2.1.1 Solutions for acid-fast staining 
Staining solution: 0.8% carbolfuchsin solution 
Destaining solution: 3% hydrochloric acid- alcohol solution 
Counterstaining solution: 0.3‰ methylene blue solution 
2.1.2 Acid-fast staining procedure 
The procedures for acid-fast staining were based on the modified method described by Hu 
et al. (Hu et al., 2008). To prepare a smear for AFB, appropriate specimens were spread 
uniformly on a microscope slide, which was then fixed at 80°C for 15 minutes. Smears were 
stained with a carbolfuchsin stain and were examined using a 100× oil immersion objective 
on a light microscope. In smears stained with carbolfuchsin, AFB typically appear as purple 
to red slightly curved, short or long rods (2-8μM). They may also appear beaded or banded. 
Following is the acid-fast staining procedure: 
1. Turn on the thermostat-controlled water-bath and set up the temperature to 56°C. 
2. Air dry smear on the slide, flame fix, and transfer it to the water-bath. 
3. Add carbolfuchsin dye to the heat-fixed smear on slide for 15min, and take out the 
slide. 
4. Allow the slide to cool to room temperature, then, decolorize slide by adding the fresh 
destaining solution, and wait until red color disappears. 
5. Add counterstaining solution for 1 min, wash, and dry. 
6. Examine the slide by a 100× oil immersion objective on a light microscope. 
7. Interpret acid-fast staining results 
Smears should be carefully examined with a minimum of 300 fields, and three horizontal 
sweeps of a smear should be performed (Goodwin, 2007). The positive smear requires the 
cut-off of at least 5000 bacilli/ml. The overall sensitivity of the acid-fast staining method 
varies from 20% to 80% (Goodwin, 2007). 
2.2 Drug susceptibility testing against different drugs 
WHO has endorsed commercial liquid culture systems and molecular line-probe assays as 
gold standards for rapid detection of MDR-TB; however, because of technical complexity, 
cost and the requirement of sophisticated lab infrastructure, their uses have been limited in 
many resource-constrained settings (WHO, 2010). Several  noncommercial culture and DST 
methods have been developed for those resource-constrained settings, and assessed by 
WHO. Based on the testing results, WHO recently recommended MODS (microscopic 
observation of drug susceptibility) and NRA (nitrate reductase assay) under certain 
conditions for direct testing of sputum speciments (WHO, 2010). 
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M. tuberculosis drug susceptibility testing methods using solid media include proportional, 
resistance ratio and absolute concentration, which are inexpensive and highly standardized 
for testing susceptibility to many drugs (WHO, 2009). The proportion method is the most 
commonly used worldwide. Sputum specimens were digested, decontaminated and used to 
inoculate egg-based media such as L-J slants for DST. The instructions for the preparation of 
the egg-based media such as L-J, and detailed protocols for performing standardized 
bacteriological services for detecting infectious cases of pulmonary tuberculosis, monitoring 
treatment progress and documenting cure at the end of treatment by means of microscopic 
examination were well described by WHO in Part III (Culture) of the Laboratory Services in 
Tuberculosis Control (WHO, 1998) and should be followed strictly.  
2.2.1 Preparation of culture media 
The recommended TB diagnostic laboratory procedures (WHO, 1998; Chinese 
Antituberculosis Association, 2006) were followed for the preparation of media and 
suspension, inoculation and mycobacterium culture in a biologic safety cabinet. Löwenstein-
Jensen (L-J) solid media were prepared in the laboratory of the Affiliated Hospital of Zunyi 
Medical College. All the samples were cultured on L-J solid media and grown colonies were 
identified to the species level using TCH (2-thiophene carboxylic acid) and PNB 
(paranitrobenzoicacid) selective media or by standard biochemical procedures. 
2.2.1.1 Procedure for preparation of L-J culture medium (for 1632 ml)  
1. Dissolve salts from the following ingredients in order in about 300ml of distilled water 
by heating (WHO, 1998):  
Potassium dihydrogen phosphate anhydrous (KH2PO4)              2.4g  
Magnesium sulfate (MgSO4·7H2O)                                                  0.24g  
Magnesium citrate                                                                           0.6g  
Sodium glutamate                                                                            7.2g  
Glycerol (reagent grade)                                                               12ml  
Malachite green (2% solution)                                                        20ml  
Distilled water                                                                         600ml 
2. Add glycerol, malachite green solution and make up to 600ml with distilled water.  
3. Sterilize the solution by autoclaving at 121°C for 30 minutes.  
4. Cool the solution to room temperature.  
5. Rinse fresh hen’s eggs (not more than 7 days old) thoroughly in running water and soak 
them in 70% ethanol for 15 minutes. 
6. Crack the eggs with the edge of the beaker and pour into a sterile beaker. 
7. Stir them with an old-fashioned sterile egg beater until completely blended.  
8. Mix the sterilized solution containing all the ingredients (600ml) with homogenized 
eggs (1000ml) in a large sterile beaker (2 L capacity) and let it stand at room 
temperature for 1 hour. 
2.2.1.2 Preparation of drug-containing solid media 
Drug stock solutions at recommended concentrations (Table 1) were made in distilled 
water. To make media containing the end concentration of different drugs (Table 1), 0.4ml 
of stock solution for each drug was diluted separately with 400ml of L-J mixture 
mentioned above.  
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Media containing different drugs were distributed to sterile universal screw-cap centrifuge 
tubes (7ml medium per tube); tubes were labeled and caps were tightened. The labeled 
tubes were placed in an oven at a slanted position (30° angle) and baked at 85°C for 50 min. 
Baked tubes were cooled down to room temperature and stored at 4°C refrigerator until use. 
Since the medium was prepared with sterile precautions, this heating process was to solidify 
the medium instead of sterilizing it. The quality of the egg-based media deteriorates when 
the baking temperature is too high or the baking time is too long. The L-J medium should be 
dated and stored in the refrigerator for up to 4 weeks if the caps are tightened to prevent 
drying of the medium (WHO, 1998). 
Drug Dissolvent Diluent 
Concentration (μg/ml) 
Stock solution Drug Medium 
Capreomycin dH2O dH2O 40000 40 
Ciprofloxacin dH2O dH2O 2000 2 
Ethambutol dH2O dH2O 2000 2 
Isoniazid dH2O dH2O 200 0.2 
Levofloxacin dH2O dH2O 2000 2 
Rifampicin DMF dH2O 40000 40 
Streptomycin dH2O dH2O 4000 4 
Table 1. Recommended concentrations of anti-TB  drugs used in the drug susceptibility 
testing (WHO, 2009).  dH2O, distilled water; DMF, dimethylformamide. 
2.2.1.3 Digestion and decontamination 
M. tuberculosis grows slowly and takes four to eight weeks or longer to give visible colonies. 
Cultures are usually made in bottles because of the long incubation time required. The 
bottles are tightly capped to prevent drying of the cultures. The majority of clinical 
specimens submitted to the clinical laboratory are contaminated to varying degrees by more 
rapidly growing normal flora. These would rapidly overgrow the entire surface of the 
medium before the M. tuberculosis start to grow (Goodwin, 2007). Therefore,  specimens 
must be subjected to digestion and decontamination that liquefies the organic debris and 
eliminates the unwanted normal flora. All currently available digesting and 
decontaminating methods are to some extent toxic to M. tuberculosis. Therefore, to ensure 
the survival of the maximum number of M. tuberculosis in the specimen, the digestion and 
decontamination procedure must be precisely followed (WHO, 1998).  
2.2.2 Drug susceptibility testing 
We have collected hundreds of TB culture samples from TB patients, and used them for 
the DNA extraction and drug-susceptibility testing against seven anti-TB drugs: 
rifampicin (RIF), isoniazid (INH), streptomycin (STR), ethambutol (EMB), capreomycin 
(CPM), ciprofloxacin (CIP) and levofloxacin (LVF). The proportion method on L-J media 
was used to perform the DST against different drugs in most of clinical M. tuberculosis 
isolates. The following drug concentrations in L-J media were used for the DST: RIF, 
40μg/ml; INH, 0.2μg/ml; STR, 4µg/ml; EMB, 2µg/ml; CPM, 40µg/ml; CIP, 2µg/ml; and 
LVF, 2µg/ml.  
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2.2.3 Quality control  
After coagulation, 5% of the slopes were picked up randomly and continued for incubation 
for 2 days at 37 °C to check for sterility. If no colony was grown on the solid medium after 
48 hours of incubation at 37°C, the whole media batch should be good for DST.  
2.2.4 Results criteria  
The proportion testing results can be recorded at 28 days and again at 42 days as 3+ for 
confluent growth; 2+ for more than 100 colonies; and 1-99 colonies for the actual number of 
colonies.  The percentage of drug resistance can be expressed as: Number of colonies on 
drug-containing medium/Number of colonies on L-J medium × 100%. If the percentage >1, 
the tested bacterium is considered to be drug resistant. 
2.2.5 Results and discussion 
We analyzed 316 clinical M. tuberculosis isolates for DST against four drugs (RIF, INH, STR 
and EMB). Results showed that 51.3% of isolates were resistant to one or more drugs, 19.0% 
were MDR, 20.9% were resistant to any single drug, 12.0% were resistant to any two drugs, 
10.8% were resistant to any three drugs, and 7.6% were resistant to four drugs (Table 2). The 
prevalence of single drug-resistance was STR>RIF>EMB>INH in combined cases. There 
were 209 isolates in the first-treated (new TB cases) group, in which 42.1% were resistant to 
at least one drug,  and 23.9% were resistant to any single drug. In addition, there were 107 
isolates in the previously treated group, in which 69.2% were resistant to at least one drug,  
and 15.0% were resistant to any single drug. Our results indicated that the prevalence of 
drug-resistance in new tuberculosis cases was very high in the Zunyi area of Guizhou 
province, with 42.1% of the isolates resistant to at least one drug, and there were obvious 
differences in the drug susceptibility profiles between new and previously treated TB cases. 
These results also highlight the importance of surveillance of drug-resistant TB in order to 
improve the treatment outcomes of TB patients. 
 
Drug Susceptibility* 
PT (107 isolates) FT (209 isolates) 
Combined  
(316 isolates) 
No. of cases % No. of cases % No. of cases % 
Resistant to any single 
drug 
16 15.0 50 23.9 66 20.9 
Resistant to any 2 drugs 23 21.5 15 7.2 38 12.0 
Resistant to any 3 drugs 22 20.6 12 5.7 34 10.8 
Resistant to 4 drugs 13 12.1 11 5.3 24 7.6 
Total 74 69.2 88 42.1 162 51.3 
*Drugs tested: isoniazid, rifampincin, ethambutol and streptomycin; PT, previously treated; FT, First-
time treated (new cases). 
Table 2. Drug susceptibility profiles of 316 clinical M. tuberculosis isolates.  
3. Molecular characterization of drug-resistant M. tuberculosis  
The recommended standard or first-line treatment of tuberculosis includes a combination 
of four drugs, rifampicin, isoniazid, ethambutol and pyrazinamide, with or without 
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streptomycin. Resistance to the first-line anti-TB drugs has been linked to mutations in at 
least 13 genes: rpoB for rifampicin resistance, katG, inhA, kasA, ahpC, ndh, furA, and oxyR 
for isoniazid resistance, embCAB for ethambutol resistance, pncA for pyrazinamide 
resistance, and rpsL, rrs, and gidB for streptomycin resistance. Resistance to the second-
line anti-TB drugs has been linked to mutations in at least 10 genes (Banerjee, et al., 2008). 
For the detection of mutations in genes linked to rifampicin and isoniazid resistance, we 
amplified rpoB and KatG gene fragments from many drug-resistant M. tuberculosis clinical 
isolations and performed DNA sequencing analyses. We also detected mutations in 5 
other genes associated with drug-resistance (inhA, rpsl, rrs, gyrA and gyrB). Nucleotide 
sequences of primers used for PCR amplification and DNA sequencing were listed in 
Table 3. 
 
Gene Primer Sequence (5’→3’) Product Size (bp) 
rpoB 
Forward, TCAGACCACGATGACCGTTCC 
688 Reverse, GTCCATGTAGTCCACCTCAGACG 
Sequencing, TCGGCATGTCGCGGATGGAG 
katG 
Forward, GCTCGGCGATGAGCGTTAC 
409 Reverse, CTCGTAGCCGTACAGGATCTCG 
Sequencing, GCTCGGCGATGAGCGTTAC 
inhA 
Forward, TCGCAGCCACGTTACGCTC 
175 Reverse, CCAGCCGCTGTGCGATC 
Sequencing, TCGCAGCCACGTTACGCTC 
rpsl 
Forward, GGCAGCCCGCAGCGTCGTG 
211 Reverse, TGTAGCGCACACCAGGCAGGT 
Sequencing, GGCAGCCCGCAGCGTCGTG 
rrs 
Forward, TCAGGAGGAACACCGGTGGCG
253 Reverse, AATCCACATGCTCCGCCGCTTG
Sequencing, TCAGGAGGAACACCGGTGGCG
gyrA 
Forward, CAGCTACATCGACTATGCGA
320 Reverse, GGGCTTCGGTGTACCTCAT
Sequencing, CAGCTACATCGACTATGCGA 
gyrB 
Forward, CGCAAGTCCGAACTGTATGTCGTAG
346 Reverse, GTTGTGCCAAAAACACATGC
Sequencing, CGCAAGTCCGAACTGTATGTCGTAG 
Table 3. Primers used in this study for PCR amplification and DNA sequencing 
3.1 Determination of mutation profiles in drug-related genes 
3.1.1 DNA isolation and PCR amplification 
The genomic DNA was extracted from M. tuberculosis clinical isolates using a Bacterial DNA 
Kit (Tiangen, China) following the manufacturer’s instruction. DNA fragments for 7 drug-
related genes were amplified by PCR using synthetic oligonucleotide primers listed in Table 
3. The following thermocycler parameters were applied with initial denaturation at 94°C for 
5 min; 35-42 cycles of denaturation at 94°C for 30 sec; primer annealing at 58-62°C for 30 sec; 
extension at 72°C for 30-60 sec; and a final extension at 72°C for 7 min. The obtained DNA 
www.intechopen.com
 
Understanding Tuberculosis – Global Experiences and Innovative Approaches to the Diagnosis 
 
442 
fragments were analyzed by electrophoresis in 2.0% agarose gel and were visualized under 
UV light on a transilluminator. 
3.1.2 DNA sequencing analysis 
In order to determine mutation profiles of 7 drug-related genes (rpoB, katG, inhA, rpsl, rrs, 
gyrA and gyrB), we purified PCR-amplified gene fragments and sent them to Shanghai 
Invitrogen for DNA sequencing using primers listed in Table 3. The FinchTV program was 
downloaded from Geospiza’s website and used to view the original sequencing data. 
Sequence alignment analysis was conducted using the BLAST program at the NCBI website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to compare our sequencing results with those 
wild-type M. tuberculosis genes listed in the GenBank. 
3.1.3 Results and discussion 
In 32 rifampicin-resistant strains, we identified 13 different types of missense mutations at 
codons 509, 511, 516, 522, 526, 531, 533, 550 and 572 of rpoB gene, and compared the 
mutation profile with those of rifampicin-resistant M. Tuberculosis isolates from different 
geographical regions of the world. Comparison of the results showed that the rpoB gene 
mutation profile in rifampicin-resistant M. Tuberculosis clinical isolates from Guizhou 
province differed not only from other provinces of China but also from other countries of 
Asia, Europe and America (Chen et al., 2010). Two new mutations (Val550Leu and 
Ser509Arg) were identified and deposited in GenBank (GQ250580 and GQ250581). We 
concluded that mutation profiles of rifampicin-resistant M. Tuberculosis isolates were 
variable depending on the geographical locations, and further studies would be needed to 
determine the molecular basis for such variations (Chen et al., 2010). 
In 30 isoniazid-resistant strains, 18 (60%) of them had mutations in katG and/or inhA genes 
and two newly identified mutations in katG gene (Val230Met and Pro232Gln) were 
deposited to GenBank (GQ250582 and GQ250583). Results from this study further 
confirmed that mutations in katG and inhA genes are related to the isoniazid resistance in M. 
tuberculosis (Chen Y et al., 2010).  
To better compare drug resistance and mutation profiles of clinical M. Tuberculosis isolates 
collected at our hospital, we selected 23 representative isolates and combined the DST 
results against 4 drugs with mutation profiles in 7 genes related to drug resistance in the 
same table (Table 4).  It is clear that the relationship between drug resistance and mutations 
in specific genes may be more complex than we expected. For example, no mutations were 
found in 6 of the 7 drug-related genes for isolate number 2, which was resistant to all 4 
drugs tested, suggesting that there must be changes in other regions of the genes or other 
genes. Further studies will be needed to determine the molecular mechanism underlining 
the resistance of this kind of isolates to different anti-TB drugs. In another example, two 
mutations were identified in isolate number 17, one in rpoB gene (TCG531TTG) and another 
in  katG gene (AGC315ACC). However, isolate number 17 was resistant only to rifampicin 
but sensitive to 3 other drugs. It will be necessary for us to repeat the DST for this isolate to 
confirm whether this isolate does have a mutation in katG gene but still sensitive to 
isoniazid. In summary, more studies are need to identify new genes related to MDR-TB.  
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No. R H S E
Mutations in specific resistant genes 
rpoB katG inhA rpsL rrs gyrA gyrB 
1 r r r r
TCG531T
TG 
AGC315A
CC 
CCG232C
AG 
GGC237G
AG 
GAG340A
AG 
 
CGT16G
GT 
GGA23C
GA 
WT WT NA WT 
2 r r r r WT WT WT WT WT NA WT 
3 r r r r
CTG533C
CG 
AGC315A
CC 
WT 
AAG43A
GG 
WT NA WT 
4 r r r r
CAC526T
AC 
WT WT WT WT NA WT 
5 r r r r
CAC526G
AC 
WT WT WT WT 
GCG90GT
G 
AGC95AC
C 
NA 
6 r r r s WT WT 
GCC5TC
C 
WT WT 
AGC95AC
C 
WT 
7 r r r s
GAC516G
TC 
 
AGC315A
CC 
 
GCC5TC
C 
ACT6AG
T 
NA WT 
GCG90GT
G 
AGC95AC
C 
WT 
8 r r r r
CTG533C
CG 
GTG230A
TG 
GCC5TC
C 
NA NA NA NA 
9 r r r r WT WT 
GCC5TC
C 
WT WT 
AGC95AC
C 
WT 
10 r r r s
TCG531T
TG 
AGC315A
CC 
GCC5TC
C 
GAA7G
CA 
GGG8GC
T 
 
WT WT NA WT 
11 r r r r
TCG531T
TG 
WT 
GCC5TC
C 
WT WT NA WT 
12 r r r s
CAC526G
AC 
WT WT 
AAG43A
GG 
WT 
GCG90GT
G 
AGC95AC
C 
 
WT 
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No. R H S E
Mutations in specific resistant genes 
rpoB katG inhA rpsL rrs gyrA gyrB 
13 r r r r
CAC526T
AC 
AGC315A
CC 
WT WT WT 
 
GAC94GG
C 
AGC95AC
C 
GAG528G
CG 
14 r r s r
TCG522T
TG 
GTG550T
TG 
AGC315A
CC 
WT WT WT 
ACC80AT
C 
AGC95AC
C 
WT 
15 r r r r
TCG531T
TG 
AGC315A
CC 
WT WT WT 
AGC95AC
C 
WT 
16 r r r r
TCG531T
TG 
AGC315A
CC 
WT 
AAG43A
GG 
WT 
GAC94GG
C 
AGC95AC
C 
ACC539C
CC 
17 r s s s
TCG531T
TG 
AGC315A
CC 
WT NA NA NA NA 
18 r r r r
TCG531T
TG 
AGC315A
CC 
WT WT WT 
AGC95AC
C 
WT 
19 r r r s
CTG511C
CG 
GAC516A
AC 
WT WT 
AAG43A
GG 
WT 
AGC95AC
C 
WT 
20 s r r s
CTG533C
CG 
AGC315A
CC 
WT NA NA NA NA 
21 r r r r
TCG522T
TG 
GTG550T
TG 
AGC315A
CC 
WT WT WT 
AGC95AC
C 
WT 
22 r r r r
TCG531T
TG 
AGC315A
CC 
WT 
AAG43A
GG 
WT 
AGC95AC
C 
WT 
23 r r s r
AGC509A
GG 
CTG511C
CG 
GAC516G
TC 
Gene loss WT NA WT NA WT 
Abbreviations: R, rifampicin; H, isoniazid; S, streptomycin; E, ethambutol; s, susceptible; r, resistant; 
WT, wild type; and NA, data not available. 
Table 4. Drug susceptibility profiles and mutational patterns of 23 representative clinical 
isolates 
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3.2 Genotyping 
3.2.1 Spoligotyping and its application in surveillance 
Spacer oligonucleotide typing (Spoligotyping) is a molecular method used to differentiate 
M. Tuberculosis Complex (MTC) isolates. This method is based on PCR analysis of 
polymorphisms in the MTC direct repeat (DR) chromosomal region containing multiple 
36bp DR loci. Each DR is interspersed by a unique spacer sequence of 35 to 41 bp. After PCR 
amplification, the fragment containing the whole DR region was hybridized to specific 
oligonucleotide probes designed according to the different spacer sequences, and genotypes 
were determined depending on the hybridization patterns. The most widely used 43 sites 
were developed in 1997 by Kamerbeek et al, including 37 derived from the reference strain 
H37Rv and 6 spacers derived from M. bovis BCG (Kamerbeek et al., 1997). This method is 
more rapid and easier to perform than the standard genotyping technique based on IS6110 
profiling.  
 
Member of M. TB complex 
Characterization of Spoligotyping 
(Missing Spacers) 
Mycobacterium tuberculosis  33~36 (Viana-Niero et al., 2001)  
Mycobacterium bovis 39~43 (Soini et al., 2000; Filliol et al., 2003) 
Mycobacterium africanum 8, 9, 39 (Viana-Niero et al., 2001; Filliol et al., 2003) 
Mycobacterium microti 37, 38 (Niemann et al., 2000)  
Table 5. Characterization of M. tuberculosis complex by Spoligotyping 
MTC includes M. tuberculosis, M. bovis, M. voles and Africa mycobacterium. M. tuberculosis is 
one of the leading pathogens to human and animal, followed by M. bovis. M. tuberculosis and 
M. bovis can be distinguished from MTC by using L–J agar slants, PNB and TCH.  M. bovis 
can be quickly identified by spoligotyping. Considering the difficulties in determining M. 
vole and Africa mycobacterium by traditional methods of bacteriology, Soolingen et al.  
developed the spoligotyping method to distinguish the M. vole from MTC (van Soolinger et 
al. 1998). Results from Niemann et al. proved that M. bovis could be differentiated from M. 
Africa by spoligotyping (Niemann et al., 2000). In addition, Viana-Niero et al. also indicated 
that the spoligotyping fingerprint of M. Africa was between M. tuberculosis and M. bovis 
(Viana-Niero et al., 2001). Spoligotyping can be used to distinguish MTC members based on 
their characteristic spoligotypes (Table 5). Until now, IS6110-RFLP has been the gold 
standard for genotyping of M. tuberculosis (Majeed et al., 2004). However, a comparison 
study using IS6110-RFLP and spoligotyping indicated that the genotyping capacity of 
spoligotyping was better than IS6110-RFLP to strains containing low-copy numbers of 
IS6110 (Bauer et al., 1999).  
To study the genotypic diversity, we choose spoligotyping for molecular typing of 100 clinical 
M. tuberculosis isolates collected at the Affiliated Hospital of Zunyi Medical College from 2008 
to 2009. Bacterial growth and chromosomal DNA isolation were carried out by the method of 
Soolingen et al. (van Soolinger et al., 1991). The extracted DNA was used as a template for PCR 
amplification of the DR region of the genome with the biotinylated forward primer, 5’-
GGTTTTGGGTCTGACGAC-3’ and the reverse primer 5’-CCGAGAGGG GACGGAAAC-3’. 
The following thermocycler parameters were applied with initial denaturation at 94°C for 5 
min; 35 cycles of denaturation at 94°C for 30 s; primer annealing at 56°C for 30 s; extension at 
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72°C for 30 s; and a final extension at 72°C for 8 min. The PCR amplified products were 
hybridized to a membrane containing a set of 43 immobilized oligonucleotides, each 
corresponding to one of the unique spacer DNA sequences within the DR locus. DNAs 
isolated from M. tuberculosis H37Rv and M. bovis BCG were used as controls. The hybridized 
PCR products were incubated with 1:4000-diluted streptavidin-peroxidase conjugate 
(Boehringer) for 30min at 42°C. Detection of hybridizing DNA was done by using the 
chemiluminescent ECL (Amersham) detection system followed by exposure to X-ray film 
(Hyperfilm ECL; Amersham) in accordance with the manufacturer’s instructions.  
Spoligotypes in binary format were entered in the SITVIT database (Pasteur Institute of 
Guadeloupe). Twenty-nine distinct spoligotyping patterns were observed. In total, 20 
orphan patterns were identified and the remaining 77 were contained within 9 
superfamilies: Beijing, T1, T3, T2, MANU2, Beijing-like, U, H3 and H3-T3.  Results showed 
that almost half of the isolates were clustered to the Beijing lineage, and 13 isolates were 
clustered to the T1 lineage. 
To analyze the MTC population structure, evaluate the complicacy of the global TB 
transmission and provisional evolution of the TB genetic landscape, Institute Pasteur had 
built a genetic diversity database for the MTC DR locus in 1999. This database was updated 
to SpolDB4 (Spoligotyping Database 4) in 2006. The updated database contained 1939 
shared-types (STs) of  39,295 strains from 122 countries, which were temporarily classified 
into 62 clades/lineages (Brudey et al., 2006). In this database, the 10 most prevalent clades 
are ST1 (Beijing family), ST53 (T1), ST190 (Beijing family), ST52 (T2), ST50 (H3), ST54 
(MANU2), ST37 (T3), ST742 (H3), ST265 (Beijing family) and ST127 (H4). 
The Beijing genotype family was originally identified in China (Brudey et al., 2006) and 
defined as strains that presence of at least three spacers 35-43 and absence of spacers 1-34 
(van Soolinger et al., 1995). Beijing family strains represent at least 13% of strains worldwide 
and about half of strains in the East Asia. A total of 2,346 M. tuberculosis isolates from 13 
provinces, excluding Guizhou province, in China were genotyped by spoligotyping, and 
results showed that 74.08% of the isolates belonged to the Beijing family (Dong et al., 2010). 
Other studies also examined the relationship of Beijing genotype with drug resistance, 
however, the association between them was still not clear. The possible reasons for this 
uncertainty might be: 1) the diversity of treatment programs; 2) compliance to treatment; 3) 
different quality of anti-TB drugs; and 4) spread of different and not yet distinguished 
sublineages of the Beijing strains (Parwati et al., 2010). 
The "T" families were the most prevalent following Beijing family, belonged to modern TB 
strains, and ill-defined with more than 600 unclassified STs. The “T” families were further 
divided into 5 subclades (T1-T5) based on single spacer-differences (Brudey et al. 2006). The 
numbers of T1 and T2 families were ranked the second and third respectively after Beijing 
family in the updated SpolDB4. 
4. Application of proteomics in drug-resistant M. tuberculosis 
4.1 Proteomics and its application in tuberculosis research 
Proteomics is defined as the large-scale study of proteins, their post-translational 
modifications, and their structures and functions underlying different biological processes. 
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Proteomics enables the qualitative and quantitative analyses of proteins in complex 
biological systems, such as cells, tissues, and body fluids under specific conditions or in 
response to different stimuli (Graham et al., 2011; Lim & Elenitoba-Johnson, 2004; List et al., 
2008; Wu & Liu, 2009). Proteomics is an effective means to rapidly identify new proteins as 
diagnostic or prognostic markers and as therapeutic targets for various diseases including 
cancers, genetic diseases, and infectious diseases such as tuberculosis (Chung et al., 2007; 
Kavallaris & Marshall, 2005; Drake et al., 2005; Stulik & Butaye, 2011).  
Proteomics has been applied to the research area of M. tuberculosis (Bahk et al., 2004; He et 
al., 2003; Kumar et al., 2010; Lee et al. 1999; Mattow et al. 2001; Mustafa, 2005; Pheiffer et al., 
2005; Sharma et al., 2010; Wang et al., 2007; Zhu et al., 2003) and become an important tool to 
study functional genomics of the bacterium (Mattow et al., 2003; Jiang et al., 2006; Rison et 
al., 2007; Xie et al., 2009; Jungblut et al., 2001). Proteins from M. tuberculosis missing in 
attenuated M. bovis BCG strains were identified by using proteomics (Mattow et al., 2001). 
Comparative proteome analyses of culture supernatant proteins from virulent M. 
tuberculosis H37Rv and attenuated M. bovis BCG (Mattow et al., 2003) or H37Ra (He et al., 
2003) were performed to identify new virulent factors. Proteomics was also used for 
genome-wide analysis of the host intracellular network regulating survival of M. tuberculosis 
(Kumar et al., 2010).  It was demonstrated that protein expression by a Beijing strain was 
different from that of another clinical isolate and M. tuberculosis H37Rv (Pheiffer et al., 2005). 
The major membrane protein of virulent M. tuberculosis was characterized using proteomics 
technology (Lee et al., 1999). Xie et al. used proteomics to compare proteins of MDR-TB 
isolate with drug-sensitive isolate (Xie et al. 2009). Additionally, proteomics has been 
successfully used for vaccine design to improve protection against tuberculosis (Mollenkopf 
et al., 2004). 
The development of proteomic profiles for M. tuberculosis is needed to identify proteins that 
are differentially expressed in clinical strains with different drug susceptibility profiles such 
as MDR-TB and XDR-TB comparing to the standard strain, which can provide insights into 
the mechanisms by which the mycobacteria resistant to anti-TB drugs and the selection of 
suitable biomarkers for new diagnostics, new virulent factors and/targets for the 
development of potential therapeutics and new vaccines.   
The most commonly used method for proteomic analysis is the two-dimensional 
polyacrylamide gel electrophoresis (2-DE), which allows the separation and display of 
thousands of proteins from a complex mixture by their charges (pI) and relative molecular 
mass (Mr). Gel-separated proteins can be identified rapidly by mass spectrometry (MS), and 
such analyses permit the systematic identification of the proteome if genomic information is 
available. In this preliminary study, we used 2-DE and mass spectrometry to compare 
protein expression profiles among different clinical M. tuberculosis strains such as MDR-TB, 
XDR-TB and the reference strain H37Rv, and identified some up-regulated, down-regulated 
genes which might be associated with MDR or XDR.   
4.2 Sample preparation for MDR/XDR-TB isolates 
The sensitive strain used in this study was the standard M. tuberculosis strain H37Rv, 
which was obtained as a gift from the Chinese Centre for Disease Control and Prevention. 
Both MDR-TB and XDR-TB strains were clinical isolates collected at the Affiliated 
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Hospital of Zunyi Medical College. Five to six inoculating loops of M. tuberculosis colonies 
were scraped from improved L-J culture media and transferred to 4 ml of purified water 
in a screw-top centrifuge tube. The mycobacterium suspension was heated at 80°C for 30 
min in a water bath to inactivate M. tuberculosis, and centrifuged at 4000g for 10min for 
removing the supernatant. The precipitation was resuspended in the phosphate-buffered 
saline (pH7.4), and centrifuged at 4000g for 10min to remove the supernatant. The 
inactivated M. tuberculosis sample was resuspended in 0.3ml of lysis buffer, and 10l of 
proteinase inhibitors were added to the suspension followed by incubation at 4°C for 20 
min. The suspension was then sonicated (200W, 1min×30 times), and centrifuged at 4000g 
for 30min at  4°C. Four-fold volume of cold dimethyl ketone were added to the 
suspension and the mixture was kept at -20°C overnight for precipitating proteins. The 
protein precipitates were centrifuged at 10000g for 5min at 4°C, and resuspended in 7M 
carbamide and 2M sulfourea solution to dissolve proteins followed by centrifugation at 
4000g for 30min at 4°C. Concentration of protein samples was measured by the 
NanoDrop-1000 (Thermo, Germany) and protein samples were stored at -20°C until use. 
4.3 Two-dimensional electrophoresis (2-DE) 
Protein samples (200-300g) were resuspended in 480l of rehydration buffer and applied 
to pH 4-7 IPG strips (Amersham Biosciences) for rehydration. When IPG strips were 
rehydrated with the protein samples, isoelectric focusing (IEF) was performed in the 
following voltage mode: 0V 1h, 50V 10h fast voltage, 500V 1.5h linear voltage, 2000V 1.5h 
linear voltage, 5000V 1.5h linear voltage, 8000V 1.5h linear voltage, 8000V 70000VH fast 
voltage, and 500V 16h fast voltage. 
Equilibration was performed immediately prior to the second-dimension run, in which step 
IPG strips should be laid in the strip equilibrium solution buffer I (6 mol/L Urea, 2% SDS, 
0.375mol/L pH 8.8 Tris-HCl, 20%Glycerol, and 2% DTT), then strip equilibrium solution 
buffer II (mol/L Urea, 2% SDS, 0.375mol/L pH8.8 Tris-HCl, 20% Glycerol, and 2.5% 
Iodoacetamide) each for 14 minutes. The equilibrated IPG strip was located into prepared 
13% SDS-PAGE with low-melting point agarose smother. Following electrophoresis, 
proteins were visualized by either silver staining (analytical gels) or Coomassie Brilliant 
Blue G-250 staining (preparative gels).  
The pI and Mr gradient of the 2-DE gels were determined using an iterative calibration 
method after 2-DE gel images transferred to computer by means of the image scanner. Spot 
detection and image analysis were performed and compared using the program Progenesis 
SameSpots (Nonlinear Dynamics, UK) for 2-DE database construction. Images of MDR-TB 
and XDR-TB were compared to the gel image of the standard strain H37Rv, and protein 
spots showing differential expression levels of more than two-fold were analyzed. 
4.4 MALDI-MS and database 
Twenty protein spots of interest (5 spots from H37Rv, 10 spots from XDR-TB, and 5 up-
regulated protein spots from MDR-TB) were excised from Coomassie Brilliant Blue G-250 
stained two dimensional gels (2-DE) and digested in gel using trypsin for 18h at 37°C. 
Masses of the peptides extracted from gel slices were applied to the sample plate of a 
matrix-assisted laser desorption ionization–time-of-flight MS (MALDI-TOF-MS). Peptide 
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mass fingerprint data were searched using the Mascot search (www.matrixscience.com) of 
the National Center for Biotechnology Information (NCBI) database. 
4.5 Comparison of XDR and MDR patterns  
The comparison was repeated at least three times, and only those differences confirmed in 
all comparisons were accepted as strain specific. This study compared the proteome  
of XDR-TB clinical isolate to those of MDR-TB clinical isolate and the standard strain 
H37Rv, and demonstrated that the 2-DE protein expression patterns of XDR-TB and 
MDR-TB clinical isolates were highly correlated, but there were some visible differences 
between drug-resistant strains and the reference H37Rv strain. Results also showed that 
more basic proteins were expressed in drug-resistant M. tuberculosis isolates than in the 
standard H37Rv stain. Figure 1 shows differences among three different mycobacterium 
strains.  
 
Fig. 1. Protein expression  patterns of XDR-TB and MDR-TB clinical isolates compared to the 
standard strain H37Rv in two-dimensional electrophoresis 
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Spot 
No. 
XDR-TB MDR-TB 
H37R
v 
Spot No. 
XDR-
TB 
MDR-
TB 
H37Rv 
2984 156.1 20.42 10.68 1328 36.14 3.39 6.39 
1622 145.0 11.43 30.65 2418 31.63 3.22 3.04 
2980 99.99 9.90 3.91 1440 31.49 3.43 3.28 
1692 85.41 4.34 6.95 2679 26.51 5.71 3.25 
1813 78.84 6.39 5.42 1600 26.19 1.36 3.61 
1805 67.34 3.31 5.65 2379 13.16 1.821 1.12 
2978 49.75 5.09 2.44 2787 11.91 1.79 0.85 
1839 46.13 5.60 3.89 1994 9.77 0.90 2.11 
1245 38.84 2.79 3.15 2449 5.37 0.72 0.74 
2726 36.46 3.16 3.07     
Table 6. Expression levels of 19 proteins specifically overexpressed in the XDR-TB (protein 
expression level=number in the table×104) 
There were 19 proteins specifically overexpressed in XDR-TB (Table 6), 3 proteins up-
regulated (Table 7), 13 proteins down-regulated (Table 8) and 10 proteins disappeared in the 
XDR-TB clinical isolate compared to the reference H37Rv strain.   
 
Spot No. XDR- TB MDR-TB H37Rv 
2561 22.26 29.82 14.69 
1228 46.98 4.657 20.38 
2378 37.97 9.587 4.238 
Table 7. Expression levels of 3 up-regulated proteins in XDR-TB (protein expression 
level=number in the table×104) 
Out of these forty-five protein spots, twenty were selected for the mass spectrometry 
analysis, and only three proteins were identified by the MALDI-TOF-MS (Table 9). The 
differential expression of the ribosomal protein S3 and 19 kda major membrane protein in 
the XDR-TB strain was validated by the real-time RT-PCR (data not shown). It is not clear 
how differential expression of these three proteins contributes to the drug resistance of the 
XDR-TB. Further function analysis of these three proteins will be conducted in our 
laboratory to determine their relationship with drug resistance of XDR-TB. 
 
Spot 
No. 
XDR-TB MDR-TB H37Rv 
Spot 
No. 
XDR-
TB 
MDR-TB H37Rv 
2394 58.18 159.8 122.2 2695 5.16 17.13 13.47 
2994 43.26 11.03 92.87 2365 4.76 44.01 48.32 
2991 26.93 41.37 65.52 2989 4.56 23.36 13.34 
2499 18.92 49.45 49.02 2436 2.67 7.96 13.41 
2637 16.45 84.32 53.78 1627 1.87 1.70 11.67 
1279 11.77 18.13 36.18 2174 1.40 8.94 16.15 
1616 7.60 22.65 12.33     
Table 8. Expression levels of 13 down-regulated proteins in XDR-TB (protein expression 
quantity=number in the table×104). 
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Spot No. Protein Name Function 
2994 
MMP=19 kda major membrane 
protein 
Lipomannan, overlapping peptide 
sequences 
1994 Ribosomal protein S3 
Ribonucleoprotein, binding and 
positioning mRNA for translation 
1813 YclD Unknown 
Table 9. Description of three proteins identified by MALDI-TOF-MS 
5. Conclusion 
In this chapter, we have provided the detailed description about our current progresses in 
the field of survey and molecular characterization of drug-resistant M. tuberculosis clinical 
isolates using different research methods such as M. tuberculosis culture, spoligotyping, gene 
sequencing, proteomics and drug susceptibility testing against first-line and second-line 
anti-tuberculosis drugs. We hope this chapter will be useful for researchers, scientists and 
physicians in academic institutions, clinical laboratories, pharmaceutical companies and 
research hospitals who have interest in the research related to drug-resistant M. tuberculosis, 
especially MDR/XDR-TB. 
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